GSK Unveils Plans For Major Europe Biotech Cluster
Could Result in Up To 5,000 Jobs
The under-pressure drugs giant has something to cheer with plans for a new campus that could attract several world-class research organizations to its doorstep and bring a multi-million pound windfall from the sale of land.
You may also be interested in...
Moves by Elliott Advisors to split up GSK and unseat Emma Walmsley look unlikely to succeed, but have already created pressure for more deal-making.
The Swiss major's oncology business performed well in the third quarter with Kisqali sales catching the eye despite the specific problems that the pandemic has brought for breast cancer patients.
CEO Vas Narasimhan sees Novartis very much as an innovative company so the long-awaited strategic review of Sandoz suggests that the generics/biosimilars business could be spun off or sold fairly soon.